AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2483556 — intervention group
Group type: COMPARATOR
Intervention: Radical radiation alone
Number of subjects: 74
Study 72953 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lincomycin and tobramycin
Number of subjects: 113
Study 72953 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of povidone-iodine
Number of subjects: 113
Study 72953 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 113
Study 31087729 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (s-NPWT)
Number of subjects: 164
Study 31087729 — intervention group
Group type: COMPARATOR
Intervention: Traditional negative pressure wound therapy (t-NPWT)
Number of subjects: 164
Study 28225506 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg IV ibuprofen in 100 mL saline
Number of subjects: 60
Study 28225506 — intervention group
Group type: COMPARATOR
Intervention: 100 mL saline solution
Number of subjects: 60
Study 26188456 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased social control treatment (participants played in randomly assigned pairs of two)
Number of subjects: 0
Study 26188456 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on unethical behavior of participants in a similar experiment
Number of subjects: 0
Study 26188456 — intervention group
Group type: EXPERIMENTAL
Intervention: Online experiment with increased anonymity
Number of subjects: 0
Study 26188456 — intervention group
Group type: COMPARATOR
Intervention: Baseline treatment (subjects rolled a die in private)
Number of subjects: 0
Study 23004005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peironimev‐plus/oral/one tablet‐daily + Verapamil injection (peri‐lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week for 6 months
Number of subjects: 64
Study 23004005 — intervention group
Group type: COMPARATOR
Intervention: Verapamil injection (peri‐lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week for 6 months
Number of subjects: 64
Study 21175732 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course and planned medical consultations
Number of subjects: 33
Study 21175732 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course and shared care setting with no planned consultations
Number of subjects: 33
Study 21175732 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course and planned nursing consultations every 3 months
Number of subjects: 33
Study 21175732 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course and consultations with nurses and hospital doctors
Number of subjects: 33
Study 19843915 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation (CPVA)
Number of subjects: 60
Study 19843915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI)
Number of subjects: 60
Study 21940760 — intervention group
Group type: EXPERIMENTAL
Intervention: CX717 1000 mg
Number of subjects: 16
Study 21940760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15699235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and infants received vitamin A (Aa)
Number of subjects: 9208
Study 15699235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers received vitamin A and infants received placebo (Ap)
Number of subjects: 9208
Study 15699235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers received placebo and infants received vitamin A (Pa)
Number of subjects: 9208
Study 15699235 — intervention group
Group type: COMPARATOR
Intervention: Both mothers and infants received placebo (Pp)
Number of subjects: 9208
Study 14563516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion at a threshold of 10,000/microL
Number of subjects: 0
Study 14563516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion at a threshold of 20,000/microL
Number of subjects: 0
Study 11477926 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 39
Study 11477926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 8080670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 1 g every 8 h (n = 41)
Number of subjects: 121
Study 8080670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g every 8 h (n = 38)
Number of subjects: 121
Study 8080670 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg every 4 h (n = 42)
Number of subjects: 121
Study 8080670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (1 g or 2 g)
Number of subjects: 121
Study 8080670 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 121
Study 2583144 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 12
Study 2583144 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sucrose with electrolytes
Number of subjects: 12
Study 2583144 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sucrose with electrolytes
Number of subjects: 12
Study 2583144 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose with electrolytes
Number of subjects: 12
Study 2583144 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO beverages (6%, 8%, 10% sucrose)
Number of subjects: 12
Study 2583144 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverage treatments
Number of subjects: 12
Study 338198 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of antibodies to milk proteins in infants fed cow milk.
Number of subjects: 0
Study 338198 — intervention group
Group type: COMPARATOR
Intervention: Children with food hypersensitivity (age-matched to non-hypersensitive children).
Number of subjects: 0
Study 338198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersensitivity to food (not necessarily milk).
Number of subjects: 0
Study 28526210 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg daily for 48 weeks
Number of subjects: 93
Study 28526210 — intervention group
Group type: COMPARATOR
Intervention: As-needed β2-agonists
Number of subjects: 93
Study 27617317 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 85
Study 27617317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 85
Study 24745852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Needle insertion at intervertebral space determined by intercristal line intersecting an intervertebral space or spinous process above
Number of subjects: 110
Study 24745852 — intervention group
Group type: COMPARATOR
Intervention: Group B - Needle insertion at intervertebral space determined by intercristal line intersecting an intervertebral space or spinous process below
Number of subjects: 110
Study 24745852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 110
Study 24745852 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 110
Study 24745852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 110
Study 22503005 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml increase in dead space through a custom designed full face mask
Number of subjects: 12
Study 22503005 — intervention group
Group type: COMPARATOR
Intervention: No added dead space (control condition)
Number of subjects: 12
Study 20007752 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1490
Study 20007752 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients with high-grade stenosis
Number of subjects: 1490
Study 20007752 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 1490
Study 18334528 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma adiponectin (ADPN) levels
Number of subjects: 182
Study 18334528 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly plasma ADPN levels
Number of subjects: 182
Study 18334528 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ADPN levels
Number of subjects: 182
Study 18334528 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPN levels measured over time
Number of subjects: 182
Study 16299869 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape and brochure with practical skills for self-control and treatment
Number of subjects: 332
Study 16299869 — intervention group
Group type: COMPARATOR
Intervention: Videotape and brochure with general diabetes information
Number of subjects: 332
Study 16299869 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 332
Study 12571210 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine (RAI) administered at a dose of 12,580 kBq/mL of nodular volume (NV)
Number of subjects: 22
Study 12571210 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (PEI) followed by radioiodine (RAI)
Number of subjects: 22
Study 10353578 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of budesonide Turbuhaler administered twice daily
Number of subjects: 273
Study 10353578 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of budesonide Turbuhaler administered twice daily
Number of subjects: 273
Study 10353578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 8575948 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (21 mg to 14 mg to 7 mg, each for 30 days)
Number of subjects: 110
Study 1680600 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg kg‐1 i.v.) during exercise
Number of subjects: 19
Study 1680600 — intervention group
Group type: COMPARATOR
Intervention: Graded arm exercise
Number of subjects: 19
Study 1680600 — intervention group
Group type: COMPARATOR
Intervention: Prolonged leg exercise
Number of subjects: 19
Study 6989437 — intervention group
Group type: EXPERIMENTAL
Intervention: Five to six year programme of medical examinations and intervention to reduce coronary risk factors.
Number of subjects: 18210
Study 6989437 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on dietary reduction of plasma cholesterol, smoking cessation, regular exercise, reduced energy intake for overweight, and hypertension treatment.
Number of subjects: 18210
Study 31922375 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 168
Study 31922375 — intervention group
Group type: COMPARATOR
Intervention: LMA classic
Number of subjects: 168
Study 31922375 — intervention group
Group type: COMPARATOR
Intervention: AIR-Q
Number of subjects: 168
Study 31061025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT) feeding
Number of subjects: 0
Study 31061025 — intervention group
Group type: COMPARATOR
Intervention: Nasoduodenal tube (NDT) feeding
Number of subjects: 0
Study 28485692 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 25926410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% energy)
Number of subjects: 743
Study 25926410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% energy)
Number of subjects: 743
Study 24223927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 0
Study 24223927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21473824 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS guided group
Number of subjects: 105
Study 19683970 — intervention group
Group type: COMPARATOR
Intervention: EUR-1008 (Zenpep, pancrelipase)
Number of subjects: 53
Study 17339143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan 20 mg
Number of subjects: 58
Study 17339143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15648502 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrobatics and Balance test
Number of subjects: 493
Study 10885719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballooned NJT
Number of subjects: 30
Study 10885719 — intervention group
Group type: COMPARATOR
Intervention: Nonballooned NJT
Number of subjects: 30
Study 9170463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 141
Study 9170463 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 141
Study 1443746 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms/kg intravenously
Number of subjects: 129
Study 1443746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 10 micrograms/kg intravenously
Number of subjects: 129
Study 1443746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 3105506 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Trinitrin (10 mg per 24 hours)
Number of subjects: 18
Study 3105506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30863047 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GLY) 15.6 µg twice daily
Number of subjects: 846
Study 30863047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 30184223 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR + CSB
Number of subjects: 574
Study 30184223 — intervention group
Group type: EXPERIMENTAL
Intervention: RFR + CSB
Number of subjects: 574
Study 30184223 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR + MNP
Number of subjects: 574
Study 30184223 — intervention group
Group type: EXPERIMENTAL
Intervention: CSB
Number of subjects: 574
Study 27638878 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance interval (R-INT)
Number of subjects: 12
Study 27638878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio interval (C-INT)
Number of subjects: 12
Study 27638878 — intervention group
Group type: COMPARATOR
Intervention: Seated control (CTL)
Number of subjects: 12
Study 24899597 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation
Number of subjects: 27
Study 24899597 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 27
Study 22682718 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchscreen educational modules on nutrition and feeding (5 modules)
Number of subjects: 160
Study 20194521 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in smoking (reduced cigarettes per day >50%)
Number of subjects: 539
Study 20194521 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters
Number of subjects: 539
Study 20194521 — intervention group
Group type: COMPARATOR
Intervention: Nonreducers
Number of subjects: 539
Study 18602187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 176
Study 18602187 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 176
Study 15836660 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin + placebo alpha‐tocopherol
Number of subjects: 44
Study 15836660 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU alpha‐tocopherol + placebo atorvastatin
Number of subjects: 44
Study 15836660 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin + 800 IU alpha‐tocopherol
Number of subjects: 44
Study 15836660 — intervention group
Group type: COMPARATOR
Intervention: placebo atorvastatin + placebo alpha‐tocopherol
Number of subjects: 44
Study 11888030 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of risedronate sodium
Number of subjects: 10068
Study 11888030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10068
Study 9883220 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 MU of intravesical interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 89
Study 9883220 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 MU of intravesical interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 89
Study 9883220 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 MU of intravesical interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 89
Study 9883220 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TUR) alone
Number of subjects: 89
Study 8564655 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal breathing of 100% O2
Number of subjects: 17
Study 8564655 — intervention group
Group type: COMPARATOR
Intervention: Four deep breaths of 100% O2 within 30 seconds
Number of subjects: 17
Study 2375564 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique (switching needles)
Number of subjects: 0
Study 2375564 — intervention group
Group type: COMPARATOR
Intervention: Alternative technique (no switching needles)
Number of subjects: 0
Study 347638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OAKG)
Number of subjects: 50
Study 347638 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 31472246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 140
Study 31472246 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 140
Study 31472246 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 140
Study 31472246 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 140
Study 30396440 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to bacteria through cultural practices (e.g., consumption of unboiled milk, access to water sources)
Number of subjects: 391
Study 30396440 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial use in people and livestock
Number of subjects: 391
Study 27396427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs11615
Number of subjects: 374
Study 27396427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs3212986, rs17655, rs1047768
Number of subjects: 374
Study 24568360 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment for four weeks
Number of subjects: 70
Study 24568360 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual for four weeks
Number of subjects: 70
Study 22990178 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic concentration group
Number of subjects: 18836
Study 22990178 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS group
Number of subjects: 18836
Study 22990178 — intervention group
Group type: COMPARATOR
Intervention: BIS protocol
Number of subjects: 18836
Study 22990178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18836
Study 20188795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 52
Study 20188795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20188795 — intervention group
Group type: EXPERIMENTAL
Intervention: S'/S' genotype
Number of subjects: 52
Study 20188795 — intervention group
Group type: EXPERIMENTAL
Intervention: L/S' genotype
Number of subjects: 52
Study 17650170 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (GI) - Continuous denture wear
Number of subjects: 24
Study 17650170 — intervention group
Group type: COMPARATOR
Intervention: Group II (GII) - Daytime denture wear
Number of subjects: 24
Study 16300126 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Active Concept therapy
Number of subjects: 120
Study 16300126 — intervention group
Group type: COMPARATOR
Intervention: Untreated subjects (Control)
Number of subjects: 120
Study 12397459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radioiodine therapy (at least 2.96 GBq iodine-131, maximal administered activity 22.3 GBq)
Number of subjects: 88
Study 12397459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radioiodine therapy
Number of subjects: 88
Study 15490777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding agent/composite combination (Prime & Bond 2.1/PrismaTPH)
Number of subjects: 11
Study 15490777 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Dyract)
Number of subjects: 11
Study 15490777 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-curing glass ionomer (Fuji II LC)
Number of subjects: 11
Study 15490777 — intervention group
Group type: COMPARATOR
Intervention: All materials (P & B/TPH, Dyract, Fuji II LC)
Number of subjects: 11
Study 7646610 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with 10 mL of 1% mepivacaine hydrochloride solution (n = 87)
Number of subjects: 177
Study 7646610 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (n = 90)
Number of subjects: 177
Study 2912322 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol delivered via DDS
Number of subjects: 11
Study 2912322 — intervention group
Group type: COMPARATOR
Intervention: Clenbuterol delivered via conventional MDI
Number of subjects: 11
Study 4719668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-precipitated M protein vaccine
Number of subjects: 38
Study 4719668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aluminum hydroxide adjuvant)
Number of subjects: 38
Study 105114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 unit/kg regular insulin given intramuscularly every two hours
Number of subjects: 10
Study 105114 — intervention group
Group type: COMPARATOR
Intervention: 1.0 unit/kg regular insulin given half subcutaneously and half intravenously every 4 hours
Number of subjects: 10
Study 30950904 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 100
Study 30950904 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 100
Study 29450988 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-H-GSE
Number of subjects: 140
Study 29450988 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 140
Study 29648726 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of alendronate sodium (70 mg)
Number of subjects: 0
Study 29648726 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of alendronate sodium (70 mg)
Number of subjects: 0
Study 24222372 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 64
Study 24222372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22305242 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical leeches (8 leeches)
Number of subjects: 52
Study 22305242 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 52
Study 19640384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin
Number of subjects: 141
Study 19640384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin
Number of subjects: 141